David J. Roberts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
David J. Roberts has a total of 964 co-authors. Here are the top co-authors by number of shared publications:
- Emanuele Di Angelantonio
University of Cambridge
9 shared publications - Willem Hendrik Ouwehand
University of Cambridge
9 shared publications - Carolyn Doree
Systematic Review Initiative, NHS Blood and Transplant, Oxford, UK
6 shared publications - Rui Fa
Department of Electronic and Computer Engineering, Brunel University, Uxbridge, UB8 3PH, United Kingdom
6 shared publications - Adam S. Butterworth
University of Cambridge
5 shared publications - Asoke Kumar Nandi
Brunel University of London
5 shared publications
Latest Publications
- 19 October 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (2) , 212-214
The case for providing human leukocyte antigen-selected red cell transfusions—Are we there yet?
- 19 October 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (2) , 212-214
The case for providing human leukocyte antigen-selected red cell transfusions—Are we there yet?
- Open Access
- 2 June 2025
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 134 (1) , 28-34
Effect of supplementation with vitamin D on biochemical markers of iron status and erythropoiesis in older people: BEST-D trial
Previous observational studies suggested that vitamin D may control the absorption of iron (Fe) by inhibition of hepcidin, but the causal relevance of these associations is uncertain. Using placebo-controlled randomisation, we assessed the effects of supplementation with vitamin D on biochemical markers of Fe status and erythropoiesis in community-dwelling older people living in the UK. The BEST-D trial, designed to establish the optimum dose of vitamin D3 for future trials, had 305 participants, aged 65 years or older, randomly allocated to 4000 IU vitamin D3 (n 102), 2000 IU vitamin D3 (n 102) or matching placebo (n 101). We estimated the effect of vitamin D allocation on plasma levels of hepcidin, soluble transferrin receptor (sTfR), ferritin, Fe, transferrin, saturated transferrin (TSAT%) and the sTfR–ferritin index. Despite increases in 25-hydroxy-vitamin D, neither dose had significant effects on biochemical markers of Fe status or erythropoiesis. Geometric mean concentrations were similar in vitamin D3 arms v. placebo for hepcidin (20·7 [se 0·90] v. 20·5 [1·21] ng/ml), sTfR (0·69 [0·010] v. 0·70 [0·015] µg/ml), ferritin (97·1 [2·81] v. 97·8 [4·10] µg/l) and sTfR–ferritin ratio (0·36 [0·006] v. 0·36 [0·009]), respectively, while arithmetic mean levels were similar for Fe (16·7 [0·38] v. 17·3 [0·54] µmol/l), transferrin (2·56 [0·014] v. 2·60 [0·021] g/dl) and TSAT% (26·5 [0·60] v. 27·5 [0·85]). The proportions of participants with ferritin < 15 µg/l and TSAT < 16 % were unaltered by vitamin D3 suggesting that 12 months of daily supplementation with moderately high doses of vitamin D3 are unlikely to alter the Fe status of older adults.
- 2 June 2025
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 134 (1) , 28-34
Open AccessEffect of supplementation with vitamin D on biochemical markers of iron status and erythropoiesis in older people: BEST-D trial
Previous observational studies suggested that vitamin D may control the absorption of iron (Fe) by inhibition of hepcidin, but the causal relevance of these associations is uncertain. Using placebo-controlled randomisation, we assessed the effects of supplementation with vitamin D on biochemical markers of Fe status and erythropoiesis in community-dwelling older people living in the UK. The BEST-D trial, designed to establish the optimum dose of vitamin D3 for future trials, had 305 participants, aged 65 years or older, randomly allocated to 4000 IU vitamin D3 (n 102), 2000 IU vitamin D3 (n 102) or matching placebo (n 101). We estimated the effect of vitamin D allocation on plasma levels of hepcidin, soluble transferrin receptor (sTfR), ferritin, Fe, transferrin, saturated transferrin (TSAT%) and the sTfR–ferritin index. Despite increases in 25-hydroxy-vitamin D, neither dose had significant effects on biochemical markers of Fe status or erythropoiesis. Geometric mean concentrations were similar in vitamin D3 arms v. placebo for hepcidin (20·7 [se 0·90] v. 20·5 [1·21] ng/ml), sTfR (0·69 [0·010] v. 0·70 [0·015] µg/ml), ferritin (97·1 [2·81] v. 97·8 [4·10] µg/l) and sTfR–ferritin ratio (0·36 [0·006] v. 0·36 [0·009]), respectively, while arithmetic mean levels were similar for Fe (16·7 [0·38] v. 17·3 [0·54] µmol/l), transferrin (2·56 [0·014] v. 2·60 [0·021] g/dl) and TSAT% (26·5 [0·60] v. 27·5 [0·85]). The proportions of participants with ferritin < 15 µg/l and TSAT < 16 % were unaltered by vitamin D3 suggesting that 12 months of daily supplementation with moderately high doses of vitamin D3 are unlikely to alter the Fe status of older adults.
- Open Access
Array Genotyping of Transfusion Relevant Blood Cell Antigens in 6946 Ancestrally Diverse Subjects
Blood transfusions save millions of lives worldwide each year, yet formation of antibodies against non-self antigens remains a significant problem, particularly in frequently transfused patients. We designed and tested the Universal Blood Donor Typing (UBDT_PC1) array for automated high-throughput simultaneous typing of human erythroid, platelet, leukocyte, and neutrophil antigens (HEA, HPA, HLA, and HNA, respectively) to support selection of blood products matched beyond ABO/Rh. Typing samples from 6946 donors of European, African, Admixed American, South Asian, and East Asian ancestry at two different laboratories showed a genotype reproducibility of ≥99% for 17 244 variants, translating to 99.98%, 99.90%, and 99.93% concordance across 338 372 HEA, 53 270 HPA, and 107 094 HLA genotypes, respectively. Compared to previous clinical typing data, concordance was 99.9% and 99.6% for 245 874 HEA and 3726 HPA comparisons, respectively. HLA types were 99.1% concordant with clinical typing across 8130 comparisons, with imputation accuracy higher in Europeans versus non-Europeans. Seven variant RHD alleles, a GYPB deletion underlying the U− phenotype, and 14 high-frequency antigen negative types were also detected. Beyond blood typing, hereditary hemochromatosis-associated HFE variants were identified in 276 donors. We found that the UBDT_PC1 array can reliably type a wide range of blood cell antigens across diverse ancestries. Reproducibility and accuracy were retained when transfusion-relevant targets from the UBDT_PC1 array were incorporated into the UKBB_v2.2 genome-wide typing array. The results represent the potential for significant advancement towards improved patient care by reducing harm in transfused patients through extended matching.
Open AccessArray Genotyping of Transfusion Relevant Blood Cell Antigens in 6946 Ancestrally Diverse Subjects
Blood transfusions save millions of lives worldwide each year, yet formation of antibodies against non-self antigens remains a significant problem, particularly in frequently transfused patients. We designed and tested the Universal Blood Donor Typing (UBDT_PC1) array for automated high-throughput simultaneous typing of human erythroid, platelet, leukocyte, and neutrophil antigens (HEA, HPA, HLA, and HNA, respectively) to support selection of blood products matched beyond ABO/Rh. Typing samples from 6946 donors of European, African, Admixed American, South Asian, and East Asian ancestry at two different laboratories showed a genotype reproducibility of ≥99% for 17 244 variants, translating to 99.98%, 99.90%, and 99.93% concordance across 338 372 HEA, 53 270 HPA, and 107 094 HLA genotypes, respectively. Compared to previous clinical typing data, concordance was 99.9% and 99.6% for 245 874 HEA and 3726 HPA comparisons, respectively. HLA types were 99.1% concordant with clinical typing across 8130 comparisons, with imputation accuracy higher in Europeans versus non-Europeans. Seven variant RHD alleles, a GYPB deletion underlying the U− phenotype, and 14 high-frequency antigen negative types were also detected. Beyond blood typing, hereditary hemochromatosis-associated HFE variants were identified in 276 donors. We found that the UBDT_PC1 array can reliably type a wide range of blood cell antigens across diverse ancestries. Reproducibility and accuracy were retained when transfusion-relevant targets from the UBDT_PC1 array were incorporated into the UKBB_v2.2 genome-wide typing array. The results represent the potential for significant advancement towards improved patient care by reducing harm in transfused patients through extended matching.
- 10 April 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (15) , 1601-1609
The United Kingdom Infected Blood Inquiry: its findings and lessons for the future of transfusion
The UK Infected Blood Inquiry report was published in May 2024 after 6 years of taking oral and written evidence from patients, clinicians, blood services, government officials, and politicians about the transmission of infection by blood transfusion to thousands of patients in the 1970s through to the 1990s. The same problems with transfusion-transmitted infection occurred in many other countries in the same period, but their reviews, inquiries, and decisions about compensation occurred many years earlier than in the United Kingdom. The publication of the report has been welcomed but begs 2 important questions. Why was the inquiry so delayed in the United Kingdom? And why did it take so long to report? Furthermore, the report itself deserves scrutiny. What were its findings and lessons learned? How will the findings be implemented, and what are the implications, if any, for other countries?
- 10 April 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (15) , 1601-1609
The United Kingdom Infected Blood Inquiry: its findings and lessons for the future of transfusion
The UK Infected Blood Inquiry report was published in May 2024 after 6 years of taking oral and written evidence from patients, clinicians, blood services, government officials, and politicians about the transmission of infection by blood transfusion to thousands of patients in the 1970s through to the 1990s. The same problems with transfusion-transmitted infection occurred in many other countries in the same period, but their reviews, inquiries, and decisions about compensation occurred many years earlier than in the United Kingdom. The publication of the report has been welcomed but begs 2 important questions. Why was the inquiry so delayed in the United Kingdom? And why did it take so long to report? Furthermore, the report itself deserves scrutiny. What were its findings and lessons learned? How will the findings be implemented, and what are the implications, if any, for other countries?
- Open Access
- 15 December 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (5) , 1021-1029
Transfusion-specific alloimmune responses following blood transfusion pre–kidney transplantation
- 15 December 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (5) , 1021-1029
Open AccessTransfusion-specific alloimmune responses following blood transfusion pre–kidney transplantation
- 5 October 2024
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 31 (4) , 191
Editorial: Transfusion Clinique et Biologique in the concert of blood transfusion journals: Staying the course
- 5 October 2024
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 31 (4) , 191
Editorial: Transfusion Clinique et Biologique in the concert of blood transfusion journals: Staying the course
- Open Access
Changes in Phenotypic and Molecular Features of Naïve and Central Memory T Helper Cell Subsets following SARS-CoV-2 Vaccination
Molecular changes in lymphocytes following SARS-CoV-2 vaccination are incompletely understood. We hypothesized that studying the molecular (transcriptomic, epigenetic, and T cell receptor (TCR) repertoire) changes in CD4+ T cells following SARS-CoV-2 vaccination could inform protective mechanisms and refinement of future vaccines. We tested this hypothesis by reporting alterations in CD4+ T cell subsets and molecular features of CD4+ naïve and CD4+ central memory (CM) subsets between the unvaccinated and vaccinated groups. Compared with the unvaccinated, the vaccinated had higher HLA-DR expression in CD4+ T subsets, a greater number of differentially expressed genes (DEGs) that overlapped with key differentially accessible regions (DARs) along the chromatin linked to inflammasome activation, translation, regulation (of apoptosis, inflammation), and significant changes in clonal architecture beyond SARS-CoV-2 specificity. Several of these differences were more pronounced in the CD4+CM subset. Taken together, our observations imply that the COVID-19 vaccine exerts its protective effects via modulation of acute inflammation to SARS-CoV-2 challenge.
Open AccessChanges in Phenotypic and Molecular Features of Naïve and Central Memory T Helper Cell Subsets following SARS-CoV-2 Vaccination
Molecular changes in lymphocytes following SARS-CoV-2 vaccination are incompletely understood. We hypothesized that studying the molecular (transcriptomic, epigenetic, and T cell receptor (TCR) repertoire) changes in CD4+ T cells following SARS-CoV-2 vaccination could inform protective mechanisms and refinement of future vaccines. We tested this hypothesis by reporting alterations in CD4+ T cell subsets and molecular features of CD4+ naïve and CD4+ central memory (CM) subsets between the unvaccinated and vaccinated groups. Compared with the unvaccinated, the vaccinated had higher HLA-DR expression in CD4+ T subsets, a greater number of differentially expressed genes (DEGs) that overlapped with key differentially accessible regions (DARs) along the chromatin linked to inflammasome activation, translation, regulation (of apoptosis, inflammation), and significant changes in clonal architecture beyond SARS-CoV-2 specificity. Several of these differences were more pronounced in the CD4+CM subset. Taken together, our observations imply that the COVID-19 vaccine exerts its protective effects via modulation of acute inflammation to SARS-CoV-2 challenge.
- 19 October 2023
- Published by Elsevier in Seminars in Hematology
- Vol. 60 (4) , 182-188
Debate: Should the loss of disability adjusted life years (DALY) define the focus of Global Hematology?
- 19 October 2023
- Published by Elsevier in Seminars in Hematology
- Vol. 60 (4) , 182-188
Debate: Should the loss of disability adjusted life years (DALY) define the focus of Global Hematology?
- 23 February 2023
- Published by Wiley in Transfusion Medicine
- Vol. 33 (1) , 3-5
Blood services, COVID ‐19 and lessons being learnt: the past pandemic is not over, it's not even past
- 23 February 2023
- Published by Wiley in Transfusion Medicine
- Vol. 33 (1) , 3-5
Blood services, COVID ‐19 and lessons being learnt: the past pandemic is not over, it's not even past
- 19 December 2022
- Published by Wiley in Transfusion Medicine
- Vol. 32 (6) , 443-444
A difficult year… so keep on keeping on
- 19 December 2022
- Published by Wiley in Transfusion Medicine
- Vol. 32 (6) , 443-444
A difficult year… so keep on keeping on